Shares of Aurinia Pharmaceuticals Inc. (AUPH) hit a new 52-week high of $16.29 in yesterday's trading, marking an impressive year-to-date gain of over 80%, fueled by rising sales of its flagship drug and strong investor confidence.
Aurinia Pharmaceuticals, headquartered in Rockville, Maryland, and Edmonton, Alberta, is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical needs. Its flagship product is LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.